Vinge has advised Veeco Instruments Inc. ("Veeco"), a US company listed on NASDAQ, in its acquisition of Epiluvac AB, a privately held manufacturer of chemical vapor deposition epitaxy systems that enable advanced silicon carbide (“SiC”) applications in the electric vehicle market. Epiluvac, based in Lund, Sweden, was founded in 2013 by a highly experienced team in SiC.

Epiluvac’s technology platform combined with Veeco’s global go-to-market capabilities is expected to create a significant long-term growth driver for Veeco. Epiluvac is an early-stage revenue company with 11 employees. The purchase price for the transaction, all payable in cash, is $30 million paid at the time of closing with a potential additional $35 million in performance based earn-outs.

Vinge's team consisted of, among others, Jonas Bergström, Carl Sander, Stina Bengtsson and Robin Sultani (M&A), Sofia Bergenstråhle and Arvid Axelryd (IP), Anna Ståhlklo and Jonna Skog (Employment), Victor Ericsson and Emelie Svanberg (Tax), Nicklas Thorgerzon (IT & GDPR) and Jasmina Skandrani (Project Assistant).

 

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026